VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTech Breakthrough

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, announced it has been selected as the winner of the “Predictive Analytics Solution of the Year” in this year’s BioTech Breakthrough Awards program conducted by BioTech Breakthrough. Biotech Breakthrough is a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.

Browse The Complete News About Blockchain : Blockchain Partnership: PraSaga and Metahug Gamify Web3 Education Via Roblox

“Being named Predictive Analytics Solution of the Year validates our recent BIOiSIM platform innovations. Technologies like our unique Translational Index, which synthesizes the potential for clinical success of any drug candidate, enable smarter decisions about how to advance asset programs and ultimately improve the lives of patients in need.”

VeriSIM Life was recognized for its first-in-class “virtual drug development engine”, BIOiSIM, which combines artificial intelligence and machine learning with mechanistic modeling to make early and accurate predictions about compound safety and efficacy. This combined discovery and translational engine allows pharmaceutical researchers to preflight advancements in medicine in a fraction of the time and cost it takes today and provides far better patient outcomes.

“We are honored to receive this award from BioTech Breakthrough,” said Dr. Jo Varshney, CEO of VeriSIM Life. “Being named Predictive Analytics Solution of the Year validates our recent BIOiSIM platform innovations. Technologies like our unique Translational Index, which synthesizes the potential for clinical success of any drug candidate, enable smarter decisions about how to advance asset programs and ultimately improve the lives of patients in need.”

Future of Energy: TotalEnergies And Uber Join Forces To Accelerate The Transition Towards Electric Urban Mobility

Earlier this year, VeriSIM was awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to fund the AI-driven development of medications for substance use disorder (SUD). The company is also co-developing new drugs with Mayo Clinic in key disease areas, including oncology, hematology, bone/joint disorders, and neurological diseases.

“VeriSIM Life is empowering researchers to make decisions faster by providing meaningful insights much earlier in the drug development process with unprecedented accuracy and scalability,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “VeriSIM Life clearly stood out as a top innovator in the Biotech Breakthrough community of candidate companies for this award, and we will look to them to continue to deliver innovative solutions that further the productivity and performance in the drug discovery and research space. Congratulations on being our choice for the Predictive Analytics Solution of the Year.”

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top technology companies, solutions, and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,350 nominations from over a dozen countries.

Next-gen AI-On-Demand Platform :  European Commission Pumps in $9.15 Million to Develop Next-gen AI-On-Demand Platform

[To share your insights with us, please write to sghosh@martechseries.com] 

The post VeriSIM Life Named “Predictive Analytics Solution of the Year” by BioTech Breakthrough appeared first on AiThority.

artificial intelligence
ai
machine learning
blockchain
medicine
pharmaceutical
index
fund
biotech
life sciences